Experimental Modeling of Myeloproliferative Neoplasms
Abstract
:1. Introduction
2. Mutational Landscape of MPN
3. Experimental Models of MPN
4. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Dameshek, W. Some speculations on the myeloproliferative syndromes. Blood 1951, 6, 372–375. [Google Scholar] [CrossRef] [PubMed]
- Vainchenker, W.; Kralovics, R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood 2017, 129, 667–679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Skoda, R.; Duek, A.; Grisouard, J. Pathogenesis of myeloproliferative neoplasms. Exp. Hematol. 2015, 43, 599–608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grinfeld, J.; Nangalia, J.; Green, A. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica 2017, 102, 7–17. [Google Scholar] [CrossRef]
- Rumi, E.; Cazzola, M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 2017, 129, 680–692. [Google Scholar] [CrossRef]
- Harutyunyan, A.; Kralovics, R. Role of germline genetic factors in MPN pathogenesis. Hematol. Oncol. Clin. N. Am. 2012, 26, 1037–1051. [Google Scholar] [CrossRef]
- Hasselbalch, H.; Bjørn, M. MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediat. Inflamm. 2015, 2015, 102476. [Google Scholar] [CrossRef]
- Tefferi, A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am. J. Hematol. 2016, 91, 50–58. [Google Scholar] [CrossRef]
- Kralovics, R.; Teo, S.S.; Li, S.; Theocharides, A.; Buser, A.; Tichelli, A.; Skoda, R. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006, 108, 1377–1380. [Google Scholar] [CrossRef]
- Hermouet, S.; Bigot-Corbel, E.; Gardie, B. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediat. Inflamm. 2015, 2015, 145293. [Google Scholar] [CrossRef]
- Maxson, J.; Gotlib, J.; Pollyea, D.; Fleischman, A.; Agarwal, A.; Eide, C.; Bottomly, D.; Wilmot, B.; McWeeney, S.; Tognon, C.; et al. Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML. N. Engl. J. Med. 2013, 368, 1781–1790. [Google Scholar] [CrossRef] [PubMed]
- Olcaydu, D.; Harutyunyan, A.; Jäger, R.; Berg, T.; Gisslinger, B.; Pabinger, I.; Gisslinger, H.; Kralovics, R. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet. 2009, 41, 450–454. [Google Scholar] [CrossRef] [PubMed]
- Jones, A.; Chase, A.; Silver, R.; Oscier, D.; Zoi, K.; Wang, L.; Cario, H.; Pahl, H.; Collins, A.; Reiter, A.; et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet. 2009, 41, 446–449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kilpivaara, O.; Mukherjee, S.; Schram, A.; Wadleigh, M.; Mullally, A.; Ebert, B.; Bass, A.; Marubayashi, S.; Heguy, A.; Garcia-Manero, G.; et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat. Genet. 2009, 41, 455–459. [Google Scholar] [CrossRef]
- Vilaine, M.; Olcaydu, D.; Harutyunyan, A.; Bergeman, J.; Tiab, M.; Ramée, J.-F.; Jian-Min, C.; Kralovics, R.; Hermouet, S. Homologous recombination of wild-type JAK2, a novel early step in the development of myeloproliferative neoplasm. Blood 2011, 118, 6468–6470. [Google Scholar] [CrossRef] [Green Version]
- James, C.; Ugo, V.; Le Couédic, J.-P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garçon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434, 1144–1148. [Google Scholar] [CrossRef]
- Levine, R.; Wadleigh, M.; Cools, J.; Ebert, B.; Wernig, G.; Huntly, B.; Boggon, T.; Wlodarska, I.; Clark, J.; Moore, S.; et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7, 387–397. [Google Scholar] [CrossRef] [Green Version]
- Scott, L. The JAK2 exon 12 mutations: A comprehensive review. Am. J. Hematol. 2011, 86, 668–676. [Google Scholar] [CrossRef]
- Mead, A.; Rugless, M.; Jacobsen, S.; Schuh, A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N. Engl. J. Med. 2012, 366, 967–969. [Google Scholar] [CrossRef]
- Etheridge, S.L.; Cosgrove, M.; Sangkhae, V.; Corbo, L.; Roh, M.; Seeliger, M.; Chan, E.; Hitchcock, I. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood 2013, 123, 1059–1068. [Google Scholar] [CrossRef]
- Marty, C.; Saint Martin, C.; Pecquet, C.; Grosjean, S.; Saliba, J.; Mouton, C.; Leroy, E.; Harutyunyan, A.; Abgrall, J.-F.; Favier, R.; et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014, 123, 1372–1383. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lanikova, L.; Babosova, O.; Swierczek, S.; Wang, L.; Wheeler, D.; Divoky, V.; Korinek, V.; Prchal, J. Coexistence of gain-of-function JAK2 germline mutations with JAK2V617F in polycythemia vera. Blood 2016, 128, 2266–2270. [Google Scholar] [CrossRef] [PubMed]
- Mambet, C.; Babosova, O.; Defour, J.-P.; Leroy, E.; Necula, L.; Stanca, O.; Tatic, A.; Berbec, N.; Coriu, D.; Belickova, M.; et al. Co-occurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in MPN patients. Blood 2018, 132, 2695–2699. [Google Scholar] [CrossRef] [PubMed]
- Kapralova, K.; Horvathova, M.; Pecquet, C.; Fialova Kucerova, J.; Pospíšilová, D.; Leroy, E.; Kralova, B.; Milosevic Feenstra, J.; Schischlik, F.; Kralovics, R.; et al. Cooperation of germline JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. Blood 2016, 128, 1418–1423. [Google Scholar] [CrossRef]
- Lundberg, P.; Takizawa, H.; Kubovcakova, L.; Guo, G.; Hao-Shen, H.; Dirnhofer, S.; Orkin, S.; Manz, M.; Skoda, R. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. J. Exp. Med. 2014, 211, 2213–2230. [Google Scholar] [CrossRef] [Green Version]
- Anand, S.; Stedham, F.; Beer, P.; Gudgin, E.; Ortmann, C.; Bench, A.; Erber, W.; Green, A.; Huntly, B. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011, 118, 177–181. [Google Scholar] [CrossRef]
- James, C.; Mazurier, F.; Dupont, S.; Chaligne, R.; Lamrissi-Garcia, I.; Tulliez, M.; Lippert, E.; Mahon, F.-X.; Pasquet, J.; Etienne, G.; et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 2008, 112, 2429–2438. [Google Scholar] [CrossRef] [Green Version]
- Larsen, T.; Christensen, J.; Hasselbalch, H.; Pallisgaard, N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br. J. Haematol. 2007, 136, 745–751. [Google Scholar] [CrossRef]
- Mullally, A.; Lane, S.; Ball, B.; Megerdichian, C.; Okabe, R.; Al-Shahrour, F.; Paktinat, M.; Haydu, E.; Housman, E.; Lord, A.; et al. Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. Cancer Cell 2010, 17, 584–596. [Google Scholar] [CrossRef] [Green Version]
- Li, J.; Kent, D.; Godfrey, A.; Manning, H.; Nangalia, J.; Aziz, A.; Chen, E.; Saeb-Parsy, K.; Fink, J.; Sneade, R.; et al. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood 2014, 123, 3139–3151. [Google Scholar] [CrossRef] [Green Version]
- Kent, D.; Li, J.; Tanna, H.; Fink, J.; Kirschner, K.; Pask, D.; Silber, Y.; Hamilton, T.; Sneade, R.; Simons, B.; et al. Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion. PLoS Biol. 2013, 11, e1001576. [Google Scholar] [CrossRef] [PubMed]
- McKerrell, T.; Park, N.; Moreno, T.; Grove, C.; Ponstingl, H.; Stephens, J.; Crawley, C.; Craig, J.; Scott, M.; Hodkinson, C.; et al. Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis. Cell Rep. 2015, 10, 1239–1245. [Google Scholar] [CrossRef] [PubMed]
- Genovese, G.; Kähler, A.; Handsaker, R.; Lindberg, J.; Rose, S.; Bakhoum, S.; Chambert, K.; Mick, E.; Neale, B.; Fromer, M.; et al. Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N. Engl. J. Med. 2014, 371, 2477–2487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jaiswal, S.; Libby, P. Clonal haematopoiesis: Connecting ageing and inflammation in cardiovascular disease. Nat. Rev. Cardiol. 2019. [Google Scholar] [CrossRef]
- Prchal, J. The Significance of JAK2-Positive Test Results in a Healthy Patient. In ASH Clinical News, American Society of Hematology. 2019. Available online: https://www.ashclinicalnews.org (accessed on 1 August 2019).
- Sun, J.; Ramos, A.; Chapman, B.; Johnnidis, J.; Le, L.; Ho, Y.-J.; Klein, A.; Hofmann, O.; Camargo, F. Clonal dynamics of native haematopoiesis. Nature 2014, 514, 322–327. [Google Scholar] [CrossRef]
- Ding, J.; Komatsu, H.; Wakita, A.; Kato-Uranishi, M.; Ito, M.; Satoh, A.; Tsuboi, K.; Nitta, M.; Miyazaki, H.; Iida, S.; et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004, 103, 4198–4200. [Google Scholar] [CrossRef]
- Beer, P.; Campbell, P.; Scott, L.; Bench, A.; Erber, W.; Bareford, D.; Wilkins, B.; Reilly, J.; Hasselbalch, H.; Bowman, R.; et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood 2008, 112, 141–149. [Google Scholar] [CrossRef]
- Pikman, Y.; Lee, B.; Mercher, T.; McDowell, E.; Ebert, B.; Gozo, M.; Cuker, A.; Wernig, G.; Moore, S.; Galinsky, I.; et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia. PLoS Med. 2006, 3, e270. [Google Scholar] [CrossRef]
- Pardanani, A.; Lasho, T.; McClure, R.; Lacy, M.; Tefferi, A. Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood 2006, 107, 4572–4573. [Google Scholar] [CrossRef] [Green Version]
- Staerk, J.; Defour, J.-P.; Pecquet, C.; Leroy, E.; Poirel, H.; Brett, I.; Itaya, M.; Smith, S.; Vainchenker, W.; Constantinescu, S. Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J. 2011, 30, 4398–4413. [Google Scholar] [CrossRef]
- Constantinescu, S.; Keren, T.; Socolovsky, M.; Nam, H.; Henis, Y.; Lodish, H.; Constantinescu, S.N.; Keren, T.; Socolovsky, M.; Nam, H.; et al. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc. Natl. Acad. Sci. USA 2001, 98, 4379–4384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pecquet, C.; Chachoua, I.; Roy, A.; Balligand, T.; Vertenoeil, G.; Leroy, E.; Albu, R.-I.; Defour, J.-P.; Nivarthi, H.; Hug, E.; et al. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood 2019, 133, 2669–2681. [Google Scholar] [CrossRef] [PubMed]
- Pecquet, C.; Balligand, T.; Chachoua, I.; Roy, A.; Vertenoeil, G.; Colau, D.; Fertig, E.; Marty, C.; Nivarthi, H.; Defour, J.-P.; et al. Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. Blood 2018, 132, 4. [Google Scholar] [CrossRef]
- Scott, L.; Tong, W.; Levine, R.; Scott, M.; Beer, P.; Stratton, M.; Andrew Futreal, P.; Erber, W.; McMullin, M.; Harrison, C.; et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. N. Engl. J. Med. 2007, 356, 459–468. [Google Scholar] [CrossRef] [PubMed]
- Kralovics, R.; Guan, Y.; Prchal, J. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp. Hematol. 2002, 30, 229–236. [Google Scholar] [CrossRef]
- Scott, L.; Scott, M.; Campbell, P.; Green, A. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood 2006, 108, 2435–2437. [Google Scholar] [CrossRef]
- Tiedt, R.; Hao-Shen, H.; Sobas, M.; Looser, R.; Dirnhofer, S.; Schwaller, J.; Skoda, R. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111, 3931–3940. [Google Scholar] [CrossRef]
- Vannucchi, A.; Antonioli, E.; Guglielmelli, P.; Rambaldi, A.; Barosi, G.; Marchioli, R.; Marfisi, R.; Finazzi, G.; Guerini, V.; Fabris, F.; et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110, 840–846. [Google Scholar] [CrossRef]
- Yao, H.; Ma, Y.; Hong, Z.; Zhao, L.; Monaghan, A.S.; Hu, M.; Huang, L.-S. Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. Leukemia 2017, 31, 2122–2131. [Google Scholar] [CrossRef] [Green Version]
- Chen, E.; Beer, P.; Godfrey, A.; Ortmann, C.; Li, J.; Costa-Pereira, A.; Ingle, C.; Dermitzakis, E.; Campbell, P.; Green, A. Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling. Cancer Cell 2010, 18, 524–535. [Google Scholar] [CrossRef] [Green Version]
- Ortmann, C.; Kent, D.; Nangalia, J.; Silber, Y.; Wedge, D.; Grinfeld, J.; Baxter, E.; Massie, C.; Papaemmanuil, E.; Menon, S.; et al. Effect of Mutation Order on Myeloproliferative Neoplasms. N. Engl. J. Med. 2015, 372, 601–612. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lieschke, G.; Currie, P. Animal models of human disease: Zebrafish swim into view. Nat. Rev. Genet. 2007, 8, 353–367. [Google Scholar] [CrossRef] [PubMed]
- Baeten, J.; de Jong, J. Genetic Models of Leukemia in Zebrafish. Front. Cell Dev. Biol. 2017, 6, 115. [Google Scholar] [CrossRef] [PubMed]
- Ma, A.; Fan, A.; Ward, A.; Liongue, C.; Lewis, R.; Cheng, S.; Chan, P.; Yip, S.-F.; Liang, R.; Leung, A. A novel zebrafish jak2aV581F model shared features of human JAK2V617F polycythemia vera. Exp. Hematol. 2009, 37, 1379–1386. [Google Scholar] [CrossRef]
- Lim, K.-H.; Chang, Y.C.; Chiang, Y.H.; Lin, H.C.; Chang, C.-Y.; Lin, C.S.; Huang, L.; Wang, W.T.; Chen, G.-S.; Chou, W.C.; et al. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. Blood Cancer J. 2016, 6, e481. [Google Scholar] [CrossRef]
- Gjini, E.; Jing, C.-B.; Nguyen, A.; Reyon, D.; Gans, E.; Kesarsing, M.; Peterson, J.; Pozdnyakova, O.; Rodig, S.; Mansour, M.; et al. Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish. Dis. Models Mech. 2019, 12, dmm035790. [Google Scholar] [CrossRef]
- Dunbar, A.; Nazir, A.; Levine, R. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Curr. Protoc. Pharmacol. 2017, 77, 11–19. [Google Scholar]
- Bumm, T.; Elsea, C.; Corbin, A.; Loriaux, M.; Sherbenou, D.; Wood, L.; Deininger, J.; Silver, R.; Druker, B.; Deininger, M. Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease. Cancer Res. 2007, 66, 11156–11165. [Google Scholar] [CrossRef]
- Lacout, C.; Pisani, D.; Tulliez, M.; Moreau-Gachelin, F.; Vainchenker, W.; Villeval, J.-L.; Lacout, C.; Pisani, D.F.; Tulliez, M.; Gachelin, F.M.; et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006, 108, 1652–1660. [Google Scholar] [CrossRef]
- Wernig, G.; Mercher, T.; Okabe, R.; Levine, R.; Lee, B.; Gilliland, G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107, 4274–4281. [Google Scholar] [CrossRef]
- Zaleskas, V.; Krause, D.; Lazarides, K.; Patel, N.; Hu, Y.; Li, S.; Van Etten, R. Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F. PLoS ONE 2006, 1, e18. [Google Scholar] [CrossRef] [PubMed]
- Shide, K.; Shimoda, H.; Kumano, T.; Karube, K.; Kameda, T.; Takenaka, K.; Oku, S.; Abe, H.; Katayose, K.; Kubuki, Y.; et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008, 22, 87–95. [Google Scholar] [CrossRef] [PubMed]
- Xing, S.; Wanting, T.; Zhao, W.; Ma, J.; Wang, S.; Xu, X.; Li, Q.; Fu, X.; Xu, M.; Zhao, Z. Transgenic expression of JAK2(V617F) causes myeloproliferative disorders in mice. Blood 2008, 111, 5109–5117. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Spensberger, D.; Sook Ahn, J.; Anand, S.; Beer, P.; Ghevaert, C.; Chen, E.; Forrai, A.; Scott, L.; Ferreira, R.; et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, 116, 1528–1538. [Google Scholar] [CrossRef]
- Lu, X.; Levine, R.; Tong, W.; Wernig, G.; Pikman, Y.; Zarnegar, S.; Gilliland, G.; Lodish, H. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. USA 2006, 102, 18962–18967. [Google Scholar] [CrossRef]
- Kota, J.; Caceres, N.; Constantinescu, S. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 2008, 22, 1828–1840. [Google Scholar] [CrossRef] [Green Version]
- Ebie, A.; Fleming, K. Dimerization of the Erythropoietin Receptor Transmembrane Domain in Micelles. J. Mol. Biol. 2007, 366, 517–524. [Google Scholar] [CrossRef]
- Divoky, V.; Song, J.; Horvathova, M.; Kralova, B.; Bruchova Votavova, H.; Prchal, J.; Yoon, D. Delayed Hemoglobin Switching and Perinatal Neocytolysis in Mice with Gain-of-Function Erythropoietin Receptor. J. Mol. Med. 2015, 94, 597–608. [Google Scholar] [CrossRef]
- Chen, E.; Schneider, R.; Breyfogle, L.; Rosen, E.; Poveromo, L.; Elf, S.; Ko, A.; Brumme, K.; Levine, R.; Ebert, B.; et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood 2014, 125, 327–335. [Google Scholar] [CrossRef]
- Kameda, T.; Shide, K.; Yamaji, T.; Kamiunten, A.; Sekine, M.; Taniguchi, Y.; Hidaka, T.; Kubuki, Y.; Shimoda, H.; Marutsuka, K.; et al. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: Disease sustainer and disease accelerator. Blood 2014, 125, 304–315. [Google Scholar] [CrossRef]
- Falanga, A.; Marchetti, M. Thrombosis in Myeloproliferative Neoplasms. Semin. Thromb. Hemost. 2014, 40, 348–358. [Google Scholar] [PubMed]
- Vannucchi, A.; Guglielmelli, P. JAK2 Mutation-Related Disease and Thrombosis. Semin. Thromb. Hemost. 2013, 39, 496–506. [Google Scholar] [PubMed]
- Wang, W.; Liu, W.; Fidler, T.; Wang, Y.; Tang, Y.; Woods, B.; Welch, C.; Cai, B.; Silvestre-Roig, C.; Ai, D.; et al. Macrophage Inflammation, Erythrophagocytosis, and Accelerated Atherosclerosis in Jak2V617F Mice. Circ. Res. 2018, 123, e35–e47. [Google Scholar] [CrossRef] [PubMed]
- Zhao, B.; Keerthivasan, G.; Mei, Y.; Yang, J.; McElherne, J.; Wong, P.; Doench, J.; Feng, G.; Root, D.; Ji, P. Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 2014, 99, 1157–1167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, B.; Mei, Y.; Cao, L.; Zhang, J.; Sumagin, R.; Yang, J.; Gao, J.; Schipma, M.; Wang, Y.; Thorsheim, C.; et al. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms. J. Clin. Investig. 2017, 128, 125–140. [Google Scholar] [CrossRef] [PubMed]
- Wolach, O.; Sellar, R.; Martinod, K.; Cherpokova, D.; McConkey, M.; Chappell, R.; Silver, A.; Adams, D.; Castellano, C.; Schneider, R.; et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci. Transl. Med. 2018, 10, eaan8292. [Google Scholar] [CrossRef]
- Edelmann, B.; Gupta, N.; Schnoeder, T.; Oelschlegel, A.; Shahzad, K.; Goldschmidt, J.; Philipsen, L.; Weinert, S.; Ghosh, A.; Saalfeld, F.; et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J. Clin. Investig. 2018, 128, 4359–4371. [Google Scholar] [CrossRef]
- Teofili, L.; Martini, M.; Iachininoto, M.; Capodimonti, S.; Nuzzolo, E.; Torti, L.; Cenci, T.; Larocca, L.; Leone, G. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 2011, 117, 2700–2707. [Google Scholar] [CrossRef]
- Rosti, V.; Villani, L.; Riboni, R.; Poletto, V.; Bonetti, E.; Tozzi, L.; Bergamaschi, G.; Catarsi, P.; Dallera, E.; Novara, F.; et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 2012, 121, 360–368. [Google Scholar] [CrossRef]
- Guy, A.; Gourdou-Latyszenok, V.; Lay, N.; Peghaire, C.; Kilani, B.; Dias, J.; Duplaa, C.; Renault, M.-A.; Denis, C.; Villeval, J.; et al. Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica 2018, 104, 70–81. [Google Scholar] [CrossRef]
- Cocault, L.; Bouscary, D.; Le Bousse Kerdiles, C.; Clay, D.; Picard, F.; Gisselbrecht, S.; Souyri, M. Ectopic expression of murine TPO receptor (c-Mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood 1996, 88, 1656–1665. [Google Scholar] [CrossRef] [PubMed]
- Villeval, J.-L.; Cohen-Solal, K.; Tulliez, M.; Giraudier, S.; Guichard, J.; Burstein, S.A.; Cramer, E.; Vainchenker, W.; Wendling, F. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 1998, 90, 4369–4383. [Google Scholar] [CrossRef]
- Bhagwat, N.; Koppikar, P.; Keller, M.; Marubayashi, S.; Shank, K.; Rampal, R.; Qi, J.; Kleppe, M.; Patel, H.; Shah, S.; et al. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood 2014, 123, 2075–2083. [Google Scholar] [CrossRef] [PubMed]
- Sangkhae, V.; Etheridge, S.; Kaushansky, K.; Hitchcock, I. The thrombopoietin receptor, MPL, is critical for development of a JAK2V(617)F-induced myeloproliferative neoplasm. Blood 2014, 124, 3956–3963. [Google Scholar] [CrossRef]
- Klampfl, T.; Gisslinger, H.; Harutyunyan, A.; Nivarthi, H.; Rumi, E.; Milosevic Feenstra, J.; Them, N.; Berg, T.; Gisslinger, B.; Pietra, D.; et al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N. Engl. J. Med. 2013, 369, 2379–2390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 2007, 131, 861–872. [Google Scholar] [CrossRef] [Green Version]
- Ye, Z.; Zhan, H.; Mali, P.; Dowey, S.; Williams, D.; Jang, Y.; Dang, C.; Spivak, J.; Moliterno, A.; Cheng, L. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009, 114, 5473–5480. [Google Scholar] [CrossRef] [Green Version]
- Papapetrou, E. Modeling myeloid malignancies with patient-derived iPSCs. Exp. Hematol. 2018, 71, 77–84. [Google Scholar] [CrossRef]
- Smith, C.; Abalde-Atristain, L.; He, C.; Brodsky, R.; Braunstein, E.; Chaudhari, P.; Jang, Y.; Cheng, L.; Ye, Z. Efficient and Allele-Specific Genome Editing of Disease Loci in Human iPSCs. Mol. Ther. 2014, 23, 570–577. [Google Scholar] [CrossRef]
- Fu, Y.; Foden, J.; Khayter, C.; Maeder, M.; Reyon, D.; Joung, J.; Sander, J. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 2013, 31, 822–826. [Google Scholar] [CrossRef] [Green Version]
- Smith, C.; Gore, A.; Yan, W.; Abalde-Atristain, L.; Li, Z.; He, C.; Wang, Y.; Brodsky, R.; Zhang, K.; Cheng, L.; et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 2014, 15, 12–13. [Google Scholar] [CrossRef] [PubMed]
- Tian, L.; Piterkova, L.; Wang, L.; Ye, Z.; Cheng, L.; Wheeler, D.A.; Hakonarson, H.; Prchal, J. Whole Genome Sequencing of Four CD34+-Derived iPSC Polycythemia Vera Clones from a Single Female. Blood 2012, 120, 1755. [Google Scholar] [CrossRef]
- Saliba, J.; Hamidi, S.; Lenglet, G.; Langlois, T.; Yin, J.; Cabagnols, X.; Secardin, L.; Legrand, C.; Galy, A.; Opolon, P.; et al. Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS ONE 2013, 8, e74257. [Google Scholar] [CrossRef] [PubMed]
- Ye, Z.; Liu, C.; Lanikova, L.; Dowey, S.; He, C.; Huang, X.; Brodsky, R.; Spivak, J.; Prchal, J.; Cheng, L. Differential Sensitivity to JAK Inhibitory Drugs by Isogenic Human Erythroblasts and Hematopoietic Progenitors Generated from Patient-Specific Induced Pluripotent Stem Cells. Stem Cells 2014, 32, 269–278. [Google Scholar] [CrossRef] [PubMed]
- Verstovsek, S.; Kantarjian, H.; Mesa, R.; Pardanani, A.; Cortes-Franco, J.; Thomas, D.A.; Estrov, Z.; Fridman, J.; Bradley, E.; Erickson-Viitanen, S.; et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 2010, 363, 1117–1127. [Google Scholar] [CrossRef] [PubMed]
- Verstovsek, S.; Kantarjian, H.; Estrov, Z.; Cortes, J.; Thomas, D.; Kadia, T.; Pierce, S.; Jabbour, E.; Borthakur, G.; Rumi, E.; et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: Survival advantage in comparison to matched historical controls. Blood 2012, 120, 1202–1209. [Google Scholar] [CrossRef]
- Senquan, L.; Williams, D.; Moliterno, A.; Spivak, J.; Huang, H.; Gao, Y.; Ye, Z.; Cheng, L. Generation, Characterization and Genetic Modification of Human iPSCs Containing Calr, MPL and JAK2 Mutations Found in MPN Patients. Blood 2016, 128, 3139. [Google Scholar] [CrossRef]
- Liu, S.; Ye, Z.; Gao, Y.; He, C.; Rowley, D.; Moliterno, A.; Spivak, J.; Huang, H.; Cheng, L. Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. Stem Cell Res. 2017, 18, 57–59. [Google Scholar] [CrossRef]
- Wang, W.; Wang, T.; Kotini, A.; Iancu-Rubin, C.; Hoffman, R.; Papapetrou, E. Modeling Calreticulin-Mutant Myeloproliferative Neoplasms with Isogenic Induced Pluripotent Stem Cells. Blood 2018, 132, 4319. [Google Scholar] [CrossRef]
- Štetka, J.; Vyhlidalova, P.; Lanikova, L.; Koralkova, P.; Gursky, J.; Hlusi, A.; Flodr, P.; Hubackova, S.; Bartek, J.; Hodny, Z.; et al. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation. Oncogene 2019, 38, 1. [Google Scholar] [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lanikova, L.; Babosova, O.; Prchal, J.T. Experimental Modeling of Myeloproliferative Neoplasms. Genes 2019, 10, 813. https://doi.org/10.3390/genes10100813
Lanikova L, Babosova O, Prchal JT. Experimental Modeling of Myeloproliferative Neoplasms. Genes. 2019; 10(10):813. https://doi.org/10.3390/genes10100813
Chicago/Turabian StyleLanikova, Lucie, Olga Babosova, and Josef T. Prchal. 2019. "Experimental Modeling of Myeloproliferative Neoplasms" Genes 10, no. 10: 813. https://doi.org/10.3390/genes10100813